NCT04815083 2025-09-03
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
SBI ALApharma Canada, Inc.
Phase 3 Terminated
Clinical Trials
13 trialsNCT05101798 2025-07-28
The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT04469699 2025-03-11
NOA11
University Hospital Muenster
Phase 2 Terminated
NCT03963102 2024-07-26
Duration of Ameluz Application in Acral Actinic Keratoses Response
Royal Cornwall Hospitals Trust
Phase 4 Terminated
NCT01575275 2018-07-31
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00524485 2017-06-14
Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis
Roswell Park Cancer Institute
Phase NA Terminated
NCT01148966 2017-02-15
Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
University of Washington
Phase 1 Terminated
NCT01502605 2017-01-05
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT00663910 2017-01-02
Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer
The Cleveland Clinic
Phase EARLY_PHASE1 Terminated
NCT01351519 2016-03-17
A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
MultiCare Health System Research Institute
Phase 2 Terminated
NCT01203878 2014-12-08
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
Tennessee Clinical Research Center
Phase 4 Terminated
NCT00571558 2014-10-09
Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00865878 2011-10-21
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
DUSA Pharmaceuticals, Inc.
Phase 2 Terminated